Antiviral therapy substantially reduces hepatocellular carcinoma risk in chronic Hepatitis B patients in the indeterminate phase. Daniel Q Huang , Andrew Tran , Ming-Lun Yeh , Satoshi Yasuda , Pei-Chien Tsai , Chung-Feng Huang , Chia Yen Dai , Eiichi Ogawa , Masatoshi Ishigami , Takanori Ito , Ritsuzo Kozuka , Masaru Enomoto , Takanori Suzuki , Yoko Yoshimaru , Carmen Monica Preda , Raluca Ioana Marin , Irina Sandra , Sally Tran , Sabrina Xz Quek , Htet Htet Toe Wai Khine , Norio Itokawa , Masanori Atsukawa , Haruki Uojima , Tsunamasa Watanabe , Hirokazu Takahashi , Kaori Inoue , Mayumi Maeda , Joseph K Hoang , Lindsey Trinh , Scott Barnett , Ramsey Cheung , Seng Gee Lim , Huy N Trinh , Wan-Long Chuang , Yasuhito Tanaka , Hidenori Toyoda , Ming-Lung Yu , Mindie H Nguyen Hepatology (Baltimore, Md.)（2023）
摘要
Antiviral therapy reduces HCC risk by 70% among indeterminate phase CHB patients. These data have important implications for the potential expansion of CHB treatment criteria.
更多 查看译文
AI 理解论文
溯源树
样例
